Katrin Brauckhoff

Katrin Brauckhoff

Auto-generated profile, based on publicly available information

Katrin Brauckhoff

Department of Breast and Endocrine Surgery, Haukeland University Hospital , Bergen , Norway

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2018 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
RSRick Schneider
Rick Schneider
GRGregory W Randolph
Gregory W Randolph
GDGianlorenzo Dionigi
Gianlorenzo Dionigi
CWChe-Wei Wu
Che-Wei Wu
MBMarcin Barczynski
Marcin Barczynski
HDHenning Dralle
Henning Dralle

6 October 2018 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
CWChe-Wei Wu
Che-Wei Wu
GDGianlorenzo Dionigi
Gianlorenzo Dionigi
MBMarcin Barczynski
Marcin Barczynski
FCFeng‐Yu Chiang
Feng‐Yu Chiang
HDHenning Dralle
Henning Dralle
GRGregory W Randolph
Gregory W Randolph

17 December 2015 in World Journal of Surgery
Verified
Journal Article
Open access
PDF file
KBKatrin Brauckhoff
Katrin Brauckhoff
RVRenate Vik
Renate Vik
LSLorentz Sandvik
Lorentz Sandvik
JHJohn‐Helge Heimdal
John‐Helge Heimdal
TATurid Aas
Turid Aas
MBMichael Brauckhoff
Michael Brauckhoff
Background: Continuous vagal intraoperative neuromonitoring (CIONM) of the recurrent laryngeal nerve (RLN) may reduce the risk of RLN lesions during high‐risk endocrine neck surgery such as operation for large goiter potentially requiring transsternal surgery, advanced thyroid cancer, and recurrence.Methods: Fifty‐five consecutive patients (41 female, median age 61 years, 87 nerves at risk) underwent high‐risk endocrine neck surgery. CIONM was performed using the commercially available NIM‐Response 3.0 nerve monitoring system with automatic periodic stimulation (APS) and matching endotracheal tube electrodes (Medtronic Inc.). All CIONM events (decreased amplitude/increased latency) were recorded.Results: APS malfunction occurred on three sides (3 %). A total of 138 CIONM events were registered on 61 sides. Of 138, 47 (34 %) events were assessed as imminent (13 events) or potentially imminent (34 events) lesions, whereas 91 (66 %) were classified as artifacts. Loss of signal was observed in seven patients. Actions to restore the CIONM baseline were undertaken in 58/138 (42 %) events with a median 60 s required per action. Four RLN palsies (3 transient, 1 permanent) occurred: one in case of CIONM malfunction, two sudden without any significant previous CIONM event, and one without any CIONM event. The APS vagus electrode led to temporary damage to the vagus nerve in two patients.Conclusions: CIONM may prevent RLN palsies by timely recognition of imminent nerve lesions. In high‐risk endocrine neck surgery, CIONM may, however, be limited in its utility by system malfunction, direct harm to the vagus nerve, and particularly, inability to indicate RLN lesions ahead in time.

27 September 2023 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
ABAnders Bergenfelz
Anders Bergenfelz
MBMarcin Barczyński
Marcin Barczyński
AHAnette Heie
Anette Heie
AMAndreas Muth
Andreas Muth
CPChristian Passler
Christian Passler
MHMichael Hermann
Michael Hermann
Techniques for autofluorescence have been introduced to visualize the parathyroid glands during surgery and to reduce hypoparathyroidism after thyroidectomy. This parallel multicentre RCT investigated the use of Fluobeam® LX to visualize the parathyroid glands by autofluorescence during total thyroidectomy compared with no use. There was no restriction on the indication for surgery. Patients were randomized 1 : 1 and were blinded to the group allocation. The hypothesis was that autofluorescence enables identification and protection of the parathyroid glands during thyroidectomy. The primary endpoint was the rate of low parathyroid hormone (PTH) levels the day after surgery. Some 535 patients were randomized, and 486 patients received an intervention according to the study protocol, 246 in the Fluobeam® LX group and 240 in the control group. Some 64 patients (26.0 per cent) in the Fluobeam® LX group and 77 (32.1 per cent) in the control group had low levels of PTH after thyroidectomy (P = 0.141; relative risk (RR) 0.81, 95 per cent c.i. 0.61 to 1.07). Subanalysis of 174 patients undergoing central lymph node clearance showed that 15 of 82 (18 per cent) in the Fluobeam® LX group and 31 of 92 (33 per cent) in the control group had low levels of PTH on postoperative day 1 (P = 0.021; RR 0.54, 0.31 to 0.93). More parathyroid glands were identified during operation in patients who had surgery with Fluobeam® LX, and fewer parathyroid glands in the surgical specimen on definitive histopathology. No specific harm related to the use of Fluobeam® LX was reported. The use of autofluorescence during thyroidectomy did not reduce the rate of low PTH levels on postoperative day 1 in the whole group of patients. It did, however, reduce the rate in a subgroup of patients. Registration number: NCT04509011 (http://www.clinicaltrials.gov).

2 August 2024 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
Marco RaffaelliMarco Raffaelli
Marco Raffaelli
NVNikolaos Voloudakis
Nikolaos Voloudakis
MBMarcin Barczyński
Marcin Barczyński
KBKatrin Brauckhoff
Katrin Brauckhoff
CDCosimo Durante
Cosimo Durante
TMThomas J. Musholt
Thomas J. Musholt
Thyroid cancer is the most common endocrine malignancy and consists of a diverse group of histological entities1. Although ranging from indolent and well differentiated to aggressive and rapidly developing carcinomas, advanced disease may present in each histological subtype. Even though the characteristics of advanced thyroid cancer are recognized intuitively by experienced surgeons in the field, a common definition among scientific societies is yet to be reached2. General definitions of advanced disease are included in the broader management guidelines for each cancer subtype, such as the American Thyroid Association (ATA) guidelines for differentiated thyroid cancer (DTC)3, medullary thyroid cancer (MTC)4, and anaplastic thyroid cancer (ATC)5. In the European setting, the 2019 European Society of Medical Oncology (ESMO) guideline6 on thyroid cancer includes a subsection on the management of advanced disease for each thyroid cancer type. Given the recent progress and new developments in targeted therapy, depending on the genetic alterations of the tumour, new interest has emerged in better defining advanced thyroid disease and selecting candidates for tailored therapy, either in an adjuvant systemic or neoadjuvant setting. This is reflected in the most recent published position statement by the American Head and Neck Society (AHNS) and International Thyroid Oncology Group7, as well as the clinical practice guidelines update by ESMO for the use of systemic therapy in advanced thyroid cancer8. Nevertheless, existing efforts to define advanced thyroid cancer and to produce management guidelines have been burdened by a common denominator, the lack of high-quality evidence, especially regarding definitions and surgical management.

16 April 2016 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
KBKatrin Brauckhoff
Katrin Brauckhoff
TATurid Aas
Turid Aas
MBMartin Biermann
Martin Biermann
PHPaul Husby
Paul Husby
Purpose Traction is the most common cause of injury to the recurrent laryngeal nerve (RLN) in endocrine neck surgery. The purpose of this study was to evaluate specific alterations to the electromyogram (EMG) and verify safe alarm limits in a porcine model of sustained traction of the RLN using continuous intraoperative neuromonitoring (C-IONM). Methods Sixteen Norwegian Landrace pigs were anesthetized and intubated with a tracheal tube with a stick-on laryngeal electrode. EMG was recorded at baseline (BL) and during sustained traction applied to each RLN until 70 % amplitude decrease from BL, and during 30-min recovery. Results In 29 nerves at risk (NAR), BL amplitude and latency values were 1098 ± 418 (586–2255) μV (mean ± SD (range)) (right vagus) and 845 ± 289 (522–1634) μV (left vagus), and 4.7 ± 0.5 (4.1–5.9) ms and 7.9 ± 0.8 (6.7–9.6) ms, respectively. At 50 % amplitude decrease, latency increased by 14.0 ± 5.7 % (right side) and 14.5 ± 9.1 % (left side) compared with BL. Corresponding values for 70 % amplitude depression were 17.9 ± 6.1 % and 17.3 ± 12.8 %. Traction time to 50 and 70 % amplitude decrease ranged from 3 to 133 min and 3.9–141 min, respectively. In 16 NAR (55 %), time from 50 to 70 % reduction in amplitude was ≤5 min, but in six NAR (21 %) ≤1 min. In only 11 (38 %) of 29 nerves, the amplitude recovered to more than 50 % of BL. Conclusions Latency increase may be the first warning of RLN stretch injury. Given the short interval between 50 and 70 % amplitude reduction of the EMG, amplitude reduction by 50 % can be taken as an appropriate alert limit.